Trial Profile

Pivotal Phase 3 study of ASLAN004 for atopic dermatitis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jul 2023 According to an ASLAN Pharmaceuticals media release, the company plans to meet with the US Food and Drug Administration for an end-of-Phase 2 meeting and expects to initiate a Phase 3 clinical development program for eblasakimab in 2024.
04 Jan 2023 New trial record
03 Jan 2023 According to an ASLAN Pharmaceuticals media release, the company announced the partnership with Thermo Fisher Scientific Inc to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com